CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype
IPG0521m inhibited liver cancer growth via reducing the immunosuppressive function of Tregs, thereby boosting anti-cancer immunity. Our study paves the way for the clinical study of CCR8 antagonist in HCC and other cancers.
Authors
- Zheng Li (ORCID: https://orcid.org/0000-0002-1839-3450)
- JianFei Wang (ORCID: https://orcid.org/0000-0002-1380-7554)
- Guo-Huang Fan (ORCID: https://orcid.org/0009-0004-5222-0037)
- Zhilong Wang (ORCID: https://orcid.org/0009-0005-9260-7532)
- Junli Xue (ORCID: https://orcid.org/0000-0002-0553-6993)
- Xuebing Jia (ORCID: https://orcid.org/0009-0000-9538-8594)
- Binle Tian (ORCID: https://orcid.org/0000-0003-4497-2277)
- Jingyi Zhou (ORCID: https://orcid.org/0000-0002-6860-6469)
- Qi Li (ORCID: https://orcid.org/0000-0002-2978-2339)
- Yuanyuan Zhang (ORCID: https://orcid.org/0000-0001-6972-5606)
- Sijia Liu (ORCID: https://orcid.org/0000-0002-4050-3548)
- Na Wang (ORCID: https://orcid.org/0000-0002-5806-4379)
- Xiao Dong (ORCID: https://orcid.org/0000-0002-9114-6931)
- Mei Cao
- Wen Zhang (ORCID: https://orcid.org/0000-0003-2193-6222)
Institutions
- Tongji University (CN)
- Hubei University of Medicine (CN)
- Shanghai Jiao Tong University (CN)
- Taihe Hospital (CN)
- Shanghai Pulmonary Hospital (CN)
- Shanghai First People's Hospital (CN)
- Viva Biotech (China) (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1186/s13046-025-03286-x
- Citations
- 7
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 5.58
Funders
- National Natural Science Foundation of China